Johnson & Johnson (NYSE:JNJ) Shares Bought by Ranch Capital Advisors Inc.

Key Points

• Ranch Capital Advisors Inc. significantly increased its stake in Johnson & Johnson by 283.8%, acquiring a total of 13,209 shares valued at approximately $2.19 million as of their latest SEC filing.
• Institutional investors own 69.55% of Johnson & Johnson's stock, with notable increases in holdings reported by major funds like Northern Trust Corp and Bank of New York Mellon Corp.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, resulting in an annualized dividend yield of 3.0%, set to be paid on September 9th.

Ranch Capital Advisors Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 283.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,209 shares of the company's stock after buying an additional 9,767 shares during the period. Ranch Capital Advisors Inc.'s holdings in Johnson & Johnson were worth $2,191,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Northern Trust Corp raised its stake in Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after buying an additional 3,363,235 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares in the last quarter. Invesco Ltd. increased its position in shares of Johnson & Johnson by 6.5% during the fourth quarter. Invesco Ltd. now owns 19,126,079 shares of the company's stock worth $2,766,014,000 after purchasing an additional 1,171,975 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Johnson & Johnson by 2.5% during the first quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock worth $3,031,955,000 after purchasing an additional 448,666 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Johnson & Johnson by 4.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 14,773,493 shares of the company's stock worth $2,136,390,000 after purchasing an additional 636,430 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on JNJ shares. Guggenheim reiterated a "neutral" rating and set a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. UBS Group lifted their target price on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Raymond James Financial cut their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Finally, Benchmark raised Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $171.08 on Tuesday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The business's 50 day moving average is $157.82 and its two-hundred day moving average is $156.91. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $171.19. The stock has a market capitalization of $412.02 billion, a price-to-earnings ratio of 18.30, a PEG ratio of 2.13 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business's revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $2.82 EPS. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. Johnson & Johnson's payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.